Olanzapine Issued a Postive Opinion in Europe


INDIANAPOLIS, June 20 (Reuter) - Eli Lilly and Co said Thursday that
Europe's Committee for Proprietary Medicinal Products issued a positive
opinion for the marketing of Lilly's olanzapine, a drug the company hopes
to market in the treatment of schizophrenia.
The committee makes its recommendation to the European commission, which
can issue a final, single license that is valid in all 15 European union
countries.
Lilly said it expects the approval process will be completed and early
launches begun during the course of the year.
The drug currently is not approved for marketing anywhere in the world.